UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
US$ ११४.४६
arrow_downward
-०.८७%(-१.०१) 1D
अक्टोबर १६, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
US$ ११४.९५
High
US$ ११५.२८
Low
US$ ११४.२३
Mkt. cap
३९.३९ अरब
Avg. vol.
५३.३१ हजार
Volume
७०.५७ हजार
52-wk high
US$ १६८.७६
52-wk low
US$ ११०.५५
Beta
०.५७
Shares outstanding
३८.९० करोड
No. of employees
९ हजार
Open
US$ ११४.९५
High
US$ ११५.२८
Low
US$ ११४.२३
Mkt. cap
३९.३९ अरब
Avg. vol.
५३.३१ हजार
Volume
७०.५७ हजार
52-wk high
US$ १६८.७६
52-wk low
US$ ११०.५५
Beta
०.५७
Shares outstanding
३८.९० करोड
No. of employees
९ हजार
News stories
From web sources and news partners
ad-hoc-news.de
·
३ घण्टा पहिले
UCB wins FDA approval for ZILBRYSQ autoinjector and UCB stock costs EUR 203.00
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR